AUBURNDALE, Mass.--(BUSINESS WIRE)--Ovatech, an emerging women’s health-focused company, announced today that enrollment has closed for the Company’s Phase 2 clinical study of its non-hormonal, intravaginal contraceptive ring, Ovaprene. The study is being conducted at New York Downtown Hospital (NYDH), a member of the New York-Presbyterian Healthcare System. Ovaprene is a ‘one-size-fits-all’ patented, intravaginal organic silicone ring barrier-contraceptive that is designed to continuously release spermiostatic and spermicidal non-drug agents over a four-week period.
